Discovery of an ape virus in an Indonesian rodent species

The gibbon ape leukemia virus (GALV) is a medically important tool in cancer therapies. GALV is a retrovirus pathogenic to its host species, the southeast Asian lar gibbon (Hylobates lar) and thought to have originated from a cross-species transmission and may not originally be a primate virus at all. An international research team screened a wide range of rodents from southeast Asia for GALV-like sequences. The discovery of a new GALV in the grassland melomys (Melomys burtoni) from Indonesian New Guinea supports the hypothesis that this host species, and potentially related rodent lineages in Australia and Papua New Guinea, may have played a key role in the spread of GALV-like viruses.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

In conclusion, compound (1) is a selective PLK1 inhibitor that inhibits cancer cell growth. It represents a chemical scaffold for the future synthesis of new selective PLK1 inhibitors for cancer therapy.Graphical abstract
Source: Journal of Advanced Research - Category: Research Source Type: research
(UCLA Samueli School of Engineering) A cancer therapy based on fusing two types of cells into a single unit shows promise in strengthening existing treatments for acute myeloid leukemia. The approach joins blood platelets that carry cancer drugs with stem cells that guide the platelets into bone marrow where leukemia begins.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Cancer is the enemy.   So, our immediate desire is to get rid of it, throw it away, and never hear from it again.  Current therapies that require living tissue are proving that false.   We know that your living tumor tissue is like your fingerprint, unique to each individual patient.  It contains information specific to you, your genetic make-up, your cancer and ultimately the thought is, your treatment.  If kept alive, instead of being thrown away as medical waste in the operating room, it can unlock treatment options that might not otherwise be considered and save patients from side-eff...
Source: Kevin, M.D. - Medical Weblog - Category: General Medicine Authors: Tags: Conditions Oncology/Hematology Source Type: blogs
CONCLUSIONS: although the aggressiveness of treatment affects quality of life, patients consider it satisfactory after the first year. There are few significant differences between autologous and allogenic patients, and both groups have recovered in the course of the process. PMID: 30379249 [PubMed - in process]
Source: Revista Latino-Americana de Enfermagem - Category: Nursing Authors: Tags: Rev Lat Am Enfermagem Source Type: research
Publication date: Available online 19 October 2018Source: Pharmacology &TherapeuticsAuthor(s): Ryuji Yamaguchi, Lydia Lartigue, Guy PerkinsAbstractRegulation of both the extrinsic and the mitochondria-dependent intrinsic apoptotic pathways plays a key role in the development of the hematopoietic system, for sustaining cell survival during generation of various cell types, in eliminating cells with dual identities such as CD4/CD8 double-positive cells1,2, for sustaining cells during the rapid clonal expansion phase3, as well as eliminating cells during the contraction phase4. The anti-apoptotic protein Mcl-1 is necessar...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 19 October 2018Source: Pharmacology &TherapeuticsAuthor(s): Joseph T. Madak, Armand Bankhead, Christine R. Cuthbertson, Hollis D. Showalter, Nouri NeamatiAbstractIdentified as a hallmark of cancer, metabolic reprogramming allows cancer cells to rapidly proliferate, resist chemotherapies, invade, metastasize, and survive a nutrient-deprived microenvironment. Rapidly growing cells depend on sufficient concentrations of nucleotides to sustain proliferation. One enzyme essential for the de novo biosynthesis of pyrimidine-based nucleotides is dihydroorotate dehydrogenase (DHODH), a known t...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
This article provides an update of data that help inform clinicians of the role anthracyclines should play in adjuvant breast cancer therapy. Two recently reported large randomized trials—the Anthracycline in Early Breast Cancer and Western German Study Plan B studies—compared a taxane and cyclophosphamide regimen with an anthracycline, taxane, and cyclophosphamide regimen. Although the studies had conflicting results, together these studies suggest that the benefit of adjuvant anthracycline therapy over a nonanthracycline taxane‐containing regimen is modest at best and may be primarily seen in patients with ...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Review, Breast Cancer Source Type: research
ConclusionThe five novel heterocyclic compounds (E1QAC1-5) had cytotoxic effects and induced apoptosis in FD-FLT3 cells. Therefore, it is worthwhile to consider them as potential lead compound for development of new therapeutic agents for AML patients.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
nting Reactive oxygen species (ROS) are now recognized as important second messengers with roles in many aspects of signaling during leukemogenesis. They serve as critical cell signaling molecules that regulate the activity of various enzymes including tyrosine phosphatases. ROS can induce inactivation of tyrosine phosphatases, which counteract the effects of tyrosine kinases. ROS increase phosphorylation of many proteins including signal transducer and activator of transcription-5 (STAT5) via Janus kinases (JAKs). STAT5 is aberrantly activated through phosphorylation in many types of cancer and this constitutive activ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
This article reviews mechanism and therapeutic application of CRISPR/Cas9 technology, accuracy of this technology, cancer immunotherapy by CAR T cells, the application of CRISPR technology for the production of universal CAR T cells, improving their antitumor efficacy, and biotech companies that invested in CRISPR technology for CAR-T cell therapy. PMID: 30261221 [PubMed - as supplied by publisher]
Source: Human Immunology - Category: Allergy & Immunology Authors: Tags: Hum Immunol Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Indonesia Health | Leukemia | Papua New Guinea Health | Science